Gastric Breast Cancer Network Center

Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

HOME	ABOUT US	EDITORIAL BOARD	CURRENT ISSUE	PAST ISSUES	CALL FOR PAPERS

WELCOME to		GBC e - journal		Editor-in-Chief, D. Roukos, MD, PhD		WEB
LAST UPDATE: April 24, 2012		GBCNC Web Site		Associate Editor: D. Trichopoulos, MD, PhD, Harvard/ U.S		FOCUS

2010

GBC fully indexed in Scopus

SJR H Index : 1

SUBMIT YOUR PAPER

GBC

E JOURNAL

SERVICES

ARCHIVE

DOIs

NEW USER

NLM/NIH is a new subscriber to GBC

INDIVIDUALS

INSTITUTIONS/ LIBRARIES

SUBMIT A MANUSCRIPT

REVIEWERS

Links

Nature group, NEJM, JNCI, JCO

Calendar

Information

The Foundation for Hair Restoration specializes in hair transplant procedures for men and women

GBC	CURRENT ISSUE: 2012, (Apr)Vol. 11, Issue 2, pages 50-107
	EDITORIAL
	Transcriptome mapping: ER-binding sites dynamics reveal new strategy for breast cancer biomarkers Despite thousands of enthusiastic biomarkers reports, therapeutic response prediction before therapy initiation still remains a daunting challenge. Revolutionary genome-wide mapping technologies (ChIP-seq) provide unprecedented ability for transcriptome analysis. With the dynamic of ER-binding sites that has more recently reported in Nature , a new epoch of translational transcriptome mapping-based biomarkers has been launched.
	Genome-based diagnostics and therapeutics in personalized cancer therapy: Can the challenges be overcome? Although targeting cancer with antibodies and/or kinase inhibitors can improve oncological outcomes, resistance still remains a grand challenge. How could NGS technologies and systems computational biology advances result in overcoming resistance and therapeutic failure?
	PERSPECTIVE
	Science and technology: revealing genome networks for improving health Breakthrough in genome-wide mapping technologies in concert with advanced systems and synthetic biology allow us now deeper insights into structural and functional genome and cells regulation. But how can these research advances can have practical medical implementations?
	‘Sequence everything' strategy in the clinical cancer genome era As we are shifting from research to clinical whole-genome sequencing and whole-exome sequencing for cancer clinical practice, which are the challenges and how can we overcome anticancer drugs resistance and therapeutic failure in the era of personalized cancer therapy?
	Tumor heterogeneity-based personalized oncology Next-generation sequencing technologies provide the power to detect most genetic mutations and epigenetic alterations driving cancer initiation and metastasis. Is such identification underlying each individual patient sufficient to reach personalized oncological therapy or further understanding of deregulated signalling pathways network and cellular dysfunction in cancer cells is essential for achieving pragmatic improvements in cancer treatment?
	NEWS & VIEWS
	Progress in treating laparoscopically advanced gastric cancer
	Precision medicine: Neoadjuvant treatment and laparoscopic rectal cancer resection
	Laparoscopic gastrectomy: Challenges and perspectives in predicting morbidity and relapse risk in gastric cancer.
	Safety and quality of life improvement expand laparoscopic resection for gastric cancer
	Pre-treatment diagnostics of esophageal cancer and the role of EUS
	REVIEW
	Management of advanced non-clear cell renal carcinoma. Renal cell carcinoma (RCC) comprises 2-3% of all malignancies. Approximately 90% of renal tumors are RCCs, and 15% of these are non-clear cell tumors, which include papillary, chromophobe, Bellini duct (collecting duct) and sarcomatoid tumors.
	Solid cancer: Evaluating potential efficacy of epigenetic drugs. Despite targeted cancer therapy, resistance, treatment failure, disease progression and cancer death rates are still high. Can epigenetic drugs added to current standard therapeutics improve oncological outcomes of patients with solid cancer?
GBC	PAST ISSUE
	PERSPECTIVE
	From whole-genome sequencing to gene expression regulation: Perspectives for improving oncological outcomes.
	Whole-genome sequence: from research to clinical practice?
	EDITORIAL
	Inhibiting mTOR and VEGF signaling in pancreatic neuroendocrine tumors.
	COMMENTARY
	Gastric cancer recurrence: Is it influenced by laparoscopic gastrectomy
	Laparoscopic Sentinel Node Biopsy in Solid Cancer
	From Asia to Europe : Laparoscopic and robotic gastrectomy for cancer
	NEWS & VIEWS
	The up and down of KRAS testing for personalized colorectal cancer treatment.
	Monitoring EGFR plasma levels: Is it a biomarker for colorectal cancer?
	Pancreatic adenocarcinoma: a grand challenge.
	Laparoscopic Right colectomy.
	Economic crisis and laparoscopic surgery.
	REVIEW
	New standard targeted therapy for pancreatic neuroendocrine tumors.

BREAKTHROUGH PAPERS
	Nature, Green, 2011
	Cell, Hanahan, 2011
	Science, Blaxter, 2010
	Nat Rev Drug Discov, Garzon, 2010
	Science, modENCODE Consortium, 2010
	Cell, Ashworth, 2011
	Nature, de Bono, 2010
	Science, Chaffer, 2011
	Nat Biotechnol, Kelly, 2010
	Lancet, Maughan, 2011
	N Engl J Med, Chapman, 2011
	Nat Biotechnol, Feinberg, 2010
	Nat Biotechnol, Portela, 2010
	EMBO J, van Steensel, 2011
	ΚΛΗΡΟΝΟΜΙΚΟΣ ΚΑΡΚΙΝΟΣ ΜΑΣΤΟΥ - ΩΟΘΗΚΗΣ
Ο ΑΛΓΟΡΙΘΜΟΣ ΤΟΥ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΙΩΑΝΝΙΝΩΝ Ολοκληρωμένο, 4-βημάτων μοντέλο για εξατομικευμένη κλινική απόφαση : • BRCA θετικό τεστ • BRCA αρνητικό τεστ Πληροφορίες

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655 ..

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 24 April 2012